Literature DB >> 20889682

Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.

María Villa-Morales1, Elena González-Gugel, Marta N Shahbazi, Javier Santos, José Fernández-Piqueras.   

Abstract

In previous reports, we described germ line functional polymorphisms that differentiate Fas and FasL genes in two mouse strains (SEG/Pas and C57BL/6J) exhibiting extreme differences in susceptibility to γ radiation-induced T-cell lymphomas. Here, we provide new data reinforcing the importance of the extrinsic pathway of apoptosis mediated by Fas in T-cell lymphoma development and about the functional significance of polymorphisms located at intracellular and extracellular domains of Fas and FasL. Using DNA recombinant technology, we generate chimerical Fas and FasL proteins by combination of protein regions derived from the two strains and demonstrate that any Fas-FasL interaction involving chimerical proteins drive cell apoptosis to a significant lower extent than the wild-type SEG/Pas and C57BL/6J Fas-FasL systems. In addition, we report new polymorphisms in the coding sequence of Fadd and demonstrate that the interaction between Fas and Fadd is significantly stronger if Fas and Fadd are of SEG/Pas origin compared with the C57BL/6J system. Altogether, these results suggest a model in which functional polymorphisms at the three genes collaborate on the global ability of the Fas/FasL system to induce apoptosis. A complete analysis of these three genes in the pathway appears to be a sine qua non condition to accurately predict the effectiveness of the Fas system and to estimate susceptibility to T-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889682     DOI: 10.1093/carcin/bgq201

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Study of damage to red blood cells exposed to different doses of γ-ray irradiation.

Authors:  Deyi Xu; Mingxi Peng; Zhe Zhang; Guofei Dong; Yiqin Zhang; Hongwei Yu
Journal:  Blood Transfus       Date:  2012-04-26       Impact factor: 3.443

2.  Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Authors:  Wei Xiao; Mohammed L Ibrahim; Priscilla S Redd; John D Klement; Chunwan Lu; Dafeng Yang; Natasha M Savage; Kebin Liu
Journal:  Mol Cancer Res       Date:  2018-11-14       Impact factor: 5.852

3.  Genetic variation in cell death genes and risk of non-Hodgkin lymphoma.

Authors:  Johanna M Schuetz; Denise Daley; Jinko Graham; Brian R Berry; Richard P Gallagher; Joseph M Connors; Randy D Gascoyne; John J Spinelli; Angela R Brooks-Wilson
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

4.  FAS system deregulation in T-cell lymphoblastic lymphoma.

Authors:  M Villa-Morales; M A Cobos; E González-Gugel; V Álvarez-Iglesias; B Martínez; M A Piris; A Carracedo; J Benítez; J Fernández-Piqueras
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

5.  Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.

Authors:  Suketu Patel; Derek Murphy; Eugenia Haralambieva; Zainalabideen A Abdulla; Kah Keng Wong; Hong Chen; Edith Gould; Giovanna Roncador; Chris Hatton; Amanda P Anderson; Alison H Banham; Karen Pulford
Journal:  Biomark Insights       Date:  2014-09-03

6.  Polymorphism of FAS and FAS Ligand Genes in Alopecia Areata: A Case-control Study in Egyptian Population.

Authors:  Iman Seleit; Ola Ahmed Bakry; Eman Abd El Gayed; Abd El D Gawad
Journal:  Indian J Dermatol       Date:  2018 May-Jun       Impact factor: 1.494

Review 7.  FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications.

Authors:  José L Marín-Rubio; Laura Vela-Martín; José Fernández-Piqueras; María Villa-Morales
Journal:  Cancers (Basel)       Date:  2019-09-29       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.